Biopharma · FDA Approvals · Stock
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products inc…
Assets on file: AVT05
Dated catalysts for ALVO, including recently decided ones.
Nothing scheduled in this window.
Every first-hand event for ALVO, newest first.
Alvotech: FDA closes Reykjavik facility inspection with VAI classification
The FDA has formally closed its May 2026 inspection of Alvotech’s Reykjavik manufacturing site with a Voluntary Action Indicated (VAI) classification. This resolves the inspection observations and supports the company’s ongoing BLA reviews for AVT05, AVT06, and AVT16.
Alvotech resubmits BLAs for AVT05 (golimumab) and AVT06 (aflibercept)
Alvotech resubmitted the U.S. BLAs for AVT05 and AVT06 after addressing the FDA’s Post-Application Action Letter and May 2026 inspection observations. The FDA is expected to conduct a six-month review of the resubmitted applications.
Companies in the same sector closest to ALVO in market value.